SCHEMBL3537422

SCHEMBL3537422

CC1CN(C)CCN1c1ccc2[nH]c(-c3cccc4c(-c5nc6ccccc6[nH]5)n[nH]c34)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.49
FLT1 P17948 7/20 0.49
PDPK1 O15530 6/20 0.40
ABL1 P00519 1/20 0.39
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HTT P42858 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CDK2 P24941 3/20 0.38
CDK4 P11802 2/20 0.38
CCNA2 P20248 2/20 0.38
CCND1 P24385 2/20 0.38
CCND3 P30281 2/20 0.38
PDGFRB P09619 1/20 0.38
KDR P35968 1/20 0.38
USP2 O75604 1/20 0.38
PRKCZ Q05513 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540303 0.95 FGFR1 (0.55) FGFR1FLT1PDPK1ABL1NPC1
SCHEMBL3541724 0.87 FGFR1 (0.44) FGFR1FLT1PDPK1ABL1CDK2
SCHEMBL3540684 0.86 FGFR1 (0.66) FGFR1FLT1PDPK1ABL1CDK2
SCHEMBL3540882 0.84 FGFR1 (0.52) FGFR1FLT1PDPK1ABL1CDK2
SCHEMBL3540417 0.84 CDK2 (0.52) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL5866656 0.83 FGFR1 (0.52) FGFR1FLT1PDPK1ABL1NPC1
SCHEMBL5866794 0.83 FGFR1 (0.52) FGFR1FLT1PDPK1ABL1NPC1
SCHEMBL3535306 0.81 FGFR1 (0.75) FGFR1FLT1ABL1NPC1ALDH1A1
SCHEMBL3542396 0.80 FGFR1 (0.58) FGFR1FLT1PDPK1ABL1CDK2
SCHEMBL15868926 0.80 FGFR1 (0.58) FGFR1FLT1PDPK1ABL1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885PDPK1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.